📰 Loss Attributable News
Page 22 - Loss Attributable News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Loss Attributable. Real-time updates on events, politics, business and more.
August 12, 2022
Advanced RG6501 (OpRegen®) Development in Partnership with Roche and GenentechPublished OPC1 Phase 1/2a Clinical Study Results in Journal of Neurosurgery: SpineCompleted Key Activities to Support Planned Regulatory Interactions for OPC1 and VAC2Expanded Collaboration with Advanced BioMatrix for HyStem® Cell Drug Del...
August 11, 2022
Previously announced agreement for F-star Therapeutics to be acquired by invoX Pharma; transaction expected to close in the second half of 2022 License Agreement with Takeda to Develop and... | August 11, 2022
August 11, 2022
11.08.2022 - -Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1, 2022 of $53.5 million, including the additional $3 million in gross proceeds from convertible preferred financing extends funding for business ...
August 11, 2022
~ Revenue increases 514% year-over-year ~~ 21 physician workshop events completed ~LOS GATOS, CA/ ACCESSWIRE / August 11, 2022 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a
August 11, 2022
Investor Conference Call to be Held Today at 5:00 PM Eastern Time SAN DIEGO, Aug. 11, 2022 /PRNewswire/ -- Nuvve Holding Corp. , a green energy technology company that provides a...
August 11, 2022
/PRNewswire/ -- Nuvve Holding Corp. (Nuvve) (Nasdaq: NVVE), a green energy technology company that provides a globally-available, commercial vehicle-to-grid...
August 11, 2022
/PRNewswire/ -- Nuvve Holding Corp. (Nuvve) (Nasdaq: NVVE), a green energy technology company that provides a globally-available, commercial vehicle-to-grid...
August 10, 2022
Investegate announcements from Centessa Pharmaceuticals plc, Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2022; Provides Program Update for ZF874
August 10, 2022
- Registrational studies of SerpinPC for treatment of Hemophilia B planned for 2H of 2022 - - Oncology pipeline advancing with novel LockBody technology - - Announces discontinuation of ZF874
August 10, 2022
10.08.2022 - - Registrational studies of SerpinPC for treatment of Hemophilia B planned for 2H of 2022 – - Oncology pipeline advancing with novel LockBody technology – - Announces discontinuation of ZF874 for AATD – - Multiple clinical PoC readouts expected ...